The University Group Diabetes Program study in 1970 was terminated early due to excessive mortality that did not reach statistical significance in the sulphonylurea-treated group and led to tolbutamide being withdrawn from the market [ 49 ].
← all excerpts
The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes.
1
—
—